COVID-19 mRNA Vaccine Effectiveness against Elderly Frail People.

Jannis KountourasMaria Tzitiridou-Hatzopoulou Apostolis PapaefthymiouDimitrios ChatzopoulosMichael Doulberis

Published in: Medicina (Kaunas, Lithuania) (2023)

The frail, elderly population is often characterized by poor immunogenicity post COVID-19 mRNA vaccination. "Inflame-ageing" and "immune-senescence" are pathogenetic mechanisms that might explain this phenomenon. Complex interplay with cytokines and microbiota is also implicated in this inflammatory cascade. The abovementioned population, although very important from immunologic perspective, has barely been included in the mRNA vaccination clinical trials.

Keyphrases

community dwelling
coronavirus disease
sars cov
clinical trial
middle aged
binding protein
randomized controlled trial
systematic review
dna damage
oxidative stress
respiratory syndrome coronavirus
endothelial cells
phase ii
phase iii